5-Alpha-Reductase Inhibitors and Combination Therapy

Area of Science:

• Urology
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
• 5-Alpha reductase inhibitors (5ARIs) are a key therapeutic class for managing BPH.
• Prostate volume and severity of LUTS are critical factors in treatment selection.

Purpose of the Study:

• To review the efficacy of 5ARIs in treating BPH.
• To evaluate combination therapies involving 5ARIs for improved BPH management.
• To assess the safety and suitability of 5ARIs, including for elderly patients.

Main Methods:

• Review of pharmacological mechanisms of 5ARIs.
• Analysis of clinical outcomes from studies on 5ARIs and combination therapies.
• Consideration of patient-specific factors like prostate size and frailty.

Main Results:

• 5ARIs inhibit dihydrotestosterone production, leading to prostate shrinkage and LUTS improvement, especially in larger prostates (>30-40ml).
• 5ARIs generally have mild side effects and are considered suitable for frail elderly patients (FORTA classification).
• Combination therapy with alpha-blockers (ABs) demonstrated superior symptomatic outcomes and reduced clinical progression risk.
• Combining phosphodiesterase type 5 inhibitors (PDE5Is) with 5ARIs mitigates sexual side effects and enhances LUTS relief.

Conclusions:

• 5ARIs are effective for BPH, particularly for patients with larger prostates.
• Combination therapies, especially 5ARI/AB, offer significant benefits for symptomatic relief and disease progression.
• Pharmacological combinations can optimize BPH treatment by addressing efficacy and side effect profiles.